Jen-pei Liu

List of Publications by Year
in descending order

90	2,303	218677	233421
papers	citations	26 h-index	45 g-index

97	97	97	2214
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	In vitro dissolution profile comparison--statistics and analysis of the similarity factor, f2. Pharmaceutical Research, 1998, 15, 889-896.	3.5	540
2	Tests for equivalence or non-inferiority for paired binary data. Statistics in Medicine, 2002, 21, 231-245.	1.6	132
3	Better prediction of prognosis for patients with nasopharyngeal carcinoma using primary tumor volume. Cancer, 2004, 100, 2160-2166.	4.1	112
4	Sample size determination for the two one-sided tests procedure in bioequivalence. Journal of Pharmacokinetics and Pharmacodynamics, 1992, 20, 101-104.	0.6	95
5	Design and Analysis of Bioavailability and Bioequivalence Studies. , 0, , .		86
6	Radiographic Assessment of Skeletal Maturation Stages for Orthodontic Patients: Hand-wrist Bones or Cervical Vertebrae?. Journal of the Formosan Medical Association, 2008, 107, 316-325.	1.7	57
7	Predicting Healthcare Utilization Using a Pharmacy-based Metric With the WHOâ€™s Anatomic Therapeutic Chemical Algorithm. Medical Care, 2011, 49, 1031-1039.	2.4	57
8	Sample Size Determination for a Specific Region in a Multiregional Trial. Journal of Biopharmaceutical Statistics, 2010, 20, 870-885.	0.8	48
9	A nonâ€inferiority test for diagnostic accuracy based on the paired partial areas under ROC curves. Statistics in Medicine, 2008, 27, 1762-1776.	1.6	47
10	Tests of equivalence and non-inferiority for diagnostic accuracy based on the paired areas under ROC curves. Statistics in Medicine, 2006, 25, 1219-1238.	1.6	46
11	Unconditional Exact Tests for Equivalence or Noninferiority for Paired Binary Endpoints. Biometrics, 2001, 57, 478-483.	1.4	39
12	Quality of life (QOL) among community dwelling older people in Taiwan measured by the CASP-19, an index to capture QOL in old age. Archives of Gerontology and Geriatrics, 2013, 57, 143-150.	3.0	39
13	On the assessment of variability in bioavailability/bioequivalence studies. Communications in Statistics - Theory and Methods, 1992, 21, 2591-2607.	1.0	38
14	Effects of Exercise Training on Heart Rate Variability After Coronary Angioplasty. Physical Therapy, 2006, 86, 626-635.	2.4	38
15	On the exact interval estimation for the difference in paired areas under the ROC curves. Statistics in Medicine, 2008, 27, 224-242.	1.6	37
16	BAYESIAN APPROACH TO EVALUATION OF BRIDGING STUDIES. Journal of Biopharmaceutical Statistics, 2002, 12, 401-408.	0.8	34
17	USE OF THE REPEATED CROSS-OVER DESIGNS IN ASSESSING BIOEQUIVALENCE. Statistics in Medicine, 1995, 14, 1067-1078.	1.6	31
18	Statistical Assessment of Biosimilar Products. Journal of Biopharmaceutical Statistics, 2009, 20, 10-30.	0.8	31

#	Article	IF	Citations
19	Meta-analysis for bioequivalence review. Journal of Biopharmaceutical Statistics, 1997, 7, 97-111.	0.8	30
20	Use of Prior Information for Bayesian Evaluation of Bridging Studies. Journal of Biopharmaceutical Statistics, 2007, 17, 109-121.	0.8	30
21	Two-phase survey of eating disorders in gifted dance and non-dance high-school students in Taiwan. Psychological Medicine, 2007, 37, 1085-1096.	4.5	30
22	Botulinum toxin (Dysport) treatment of the spastic gastrocnemius muscle in children with cerebral palsy: a randomized trial comparing two injection volumes. Clinical Rehabilitation, 2009, 23, 64-71.	2.2	30
23	Current Issues in Bioequivalence Trials. Drug Information Journal, 1995, 29, 795-804.	0.5	29
24	BRIDGING STUDIES IN CLINICAL DEVELOPMENT. Journal of Biopharmaceutical Statistics, 2002, 12, 359-367.	0.8	28
25	Bioequivalence and intrasubject variability. Journal of Biopharmaceutical Statistics, 1991, 1, 205-219.	0.8	26
26	ASSESSMENT OF SIMILARITY BETWEEN DISSOLUTION PROFILES*. Journal of Biopharmaceutical Statistics, 2000, 10, 229-249.	0.8	26
27	Bias of two one-sided tests procedures in assessment of bioequivalence. Statistics in Medicine, 1995, 14, 853-861.	1.6	24
28	Tests for Equivalence Based on Odds Ratio for Matched-Pair Design. Journal of Biopharmaceutical Statistics, 2005, 15, 889-901.	0.8	24
29	Sample Size Requirements for Evaluation of Bridging Evidence. Biometrical Journal, 2002, 44, 969-981.	1.0	23
30	Relationship Between Age at Menarche and Skeletal Maturation Stages in Taiwanese Female Orthodontic Patients. Journal of the Formosan Medical Association, 2008, 107, 527-532.	1.7	23
31	A TWO-STAGE DESIGN FOR BRIDGING STUDIES. Journal of Biopharmaceutical Statistics, 2004, 15, 75-83.	0.8	21
32	Recent Statistical Developments in Bioequivalence Trials â€" A Review of the FDA Guidance*. Drug Information Journal, 1994, 28, 851-864.	0.5	20
33	Proposals of statistical consideration to evaluation of results for a specific region in multiâ€regional trials â€" Asian perspective. Pharmaceutical Statistics, 2010, 9, 201-206.	1.3	20
34	Immunopathological characterization of porcine circovirus type 2 infection-associated follicular changes in inguinal lymph nodes using high-throughput tissue microarray. Veterinary Microbiology, 2011, 149, 72-84.	1.9	20
35	A Group Sequential Approach to Evaluation of Bridging Studies. Journal of Biopharmaceutical Statistics, 2003, 13, 793-801.	0.8	18
36	Estimation of direct formulation effect under log-normal distribution in bioavailability/bioequivalence studies. Statistics in Medicine, 1992, 11, 881-896.	1.6	17

#	Article	IF	Citations
37	Inference on treatment effects for targeted clinical trials under enrichment design. Pharmaceutical Statistics, 2009, 8, 356-370.	1.3	17
38	A Bayesian Noninferiority Approach to Evaluation of Bridging Studies. Journal of Biopharmaceutical Statistics, 2004, 14, 291-300.	0.8	16
39	Statistical Issues on the Diagnostic Multivariate Index Assay for Targeted Clinical Trials. Journal of Biopharmaceutical Statistics, 2007, 18, 167-182.	0.8	15
40	On Statistical Evaluation of the Linearity in Assay Validation. Journal of Biopharmaceutical Statistics, 2008, 18, 677-690.	0.8	14
41	Statistical Methods for Targeted Clinical Trials under Enrichment Design. Journal of the Formosan Medical Association, 2008, 107, S35-S42.	1.7	13
42	Statistical Test for Evaluation of Biosimilarity in Variability of Follow-On Biologics. Journal of Biopharmaceutical Statistics, 2009, 20, 75-89.	0.8	13
43	A consistency approach to evaluation of bridging studies and multi-regional trials. Statistics in Medicine, 2011, 30, 2171-2186.	1.6	13
44	Evaluation of log-transformation in assessing bioequivalence. Communications in Statistics - Theory and Methods, 1994, 23, 421-434.	1.0	10
45	Noninferiority Tests Based on Concordance Correlation Coefficient for Assessment of the Agreement for Gene Expression Data from Microarray Experiments. Journal of Biopharmaceutical Statistics, 2007, 17, 309-327.	0.8	10
46	Simultaneous Non-inferiority Test of Sensitivity and Specificity for Two Diagnostic Procedures in the Presence of a Gold Standard. Biometrical Journal, 2003, 45, 47-60.	1.0	9
47	An Alternative Approach to Evaluation of Poolability for Stability Studies. Journal of Biopharmaceutical Statistics, 2006, 16, 1-14.	0.8	9
48	Statistical methods for evaluating the linearity in assay validation. Journal of Chemometrics, 2009, 23, 56-63.	1.3	9
49	Statistical Methods for Bridging Studies. Journal of Biopharmaceutical Statistics, 2012, 22, 903-915.	0.8	9
50	Prognostic factors of health careâ€“associated bloodstream infection in adult patients â‰¥40 years of age. American Journal of Infection Control, 2018, 46, 111-114.	2.3	8
51	Rethinking Statistical Approaches to Evaluating Drug Safety. Yonsei Medical Journal, 2007, 48, 895.	2.2	7
52	Statistical evaluation of nonâ€profile analyses for the in vitro bioequivalence. Journal of Chemometrics, 2010, 24, 617-625.	1.3	7
53	Immune gene expression profiles in swine inguinal lymph nodes with different viral loads of porcine circovirus type 2. Veterinary Microbiology, 2013, 162, 519-529.	1.9	7
54	Association of quality of life with laboratory measurements and lifestyle factors in community dwelling older people in Taiwan. Aging and Mental Health, 2015, 19, 548-559.	2.8	7

#	Article	IF	Citations
55	Factors associated with referral compliance of abnormal immunochemical faecal occult blood test. Journal of Medical Screening, 2007, 14, 186-190.	2.3	6
56	Deviations from linearity in statistical evaluation of linearity in assay validation. Journal of Chemometrics, 2009, 23, 487-494.	1.3	6
57	An approximate approach to sample size determination in bioequivalence testing with multiple pharmacokinetic responses. Statistics in Medicine, 2014, 33, 3300-3317.	1.6	6
58	Evaluation of parametric and nonparametric two one-sided tests procedures for assessing bioequivalence of average bioavailability. Journal of Biopharmaceutical Statistics, 1993, 3, 85-102.	0.8	5
59	Statistical evaluation of individual bioequivalence. Communications in Statistics - Theory and Methods, 1998, 27, 1433-1451.	1.0	5
60	A Two-Stage Design for Drug Screening Trials Based on Continuous Endpoints. Drug Information Journal, 2008, 42, 253-262.	0.5	5
61	Statistical Inference for the Within-Device Precision of Quantitative Measurements in Assay Validation. Journal of Biopharmaceutical Statistics, 2009, 19, 763-778.	0.8	5
62	An alternative phase II/III design for continuous endpoints. Pharmaceutical Statistics, 2011, 10, 105-114.	1.3	5
63	Applications of the Bayesian Prior Information to Evaluation of Equivalence of Similar Biological Medicinal Products. Journal of Biopharmaceutical Statistics, 2014, 24, 1254-1263.	0.8	5
64	Replicated Crossover Designs in Bioavailability and Bioequivalence Trials. Drug Information Journal, 1995, 29, 871-884.	0.5	4
65	Application of the parallel line assay to assessment of biosimilar products based on binary endpoints. Statistics in Medicine, 2013, 32, 449-461.	1.6	4
66	Statistical inference on censored data for targeted clinical trials under enrichment design. Pharmaceutical Statistics, 2013, 12, 165-173.	1.3	4
67	Letter to the Editor on â€œSample Size for Therapeutic Equivalence Based on Confidence Interval,â€•S. C. Lin, Drug Information Journal, 1995;29(1)45â€“50. Drug Information Journal, 1995, 29, 1063-1064.	0.5	3
68	An Approximate Approach to Sampling Size Determination for the Equivalence Hypothesis. Journal of Biopharmaceutical Statistics, 2013, 23, 526-538.	0.8	3
69	Targeted Clinical Trials. , 2010, , 22-1-22-11.		3
70	Statistical considerations in bioequivalence trials. Communications in Statistics - Theory and Methods, 1994, 23, 325-339.	1.0	2
71	Robustness of bioequivalence procedures under box-cox alternatives. Journal of Biopharmaceutical Statistics, 1997, 7, 135-155.	0.8	2
72	Bridging Bioequivalence Studies. Journal of Biopharmaceutical Statistics, 2004, 14, 857-867.	0.8	2

#	Article	IF	Citations
73	An inferential procedure for the probability of passing the USP dissolution test. Pharmaceutical Statistics, 2012, 11, 32-38.	1.3	2
74	Sample Size Determination for Individual Bioequivalence Inference. PLoS ONE, 2014, 9, e109746.	2.5	2
75	On difference factor in assessment of dissolution similarity. Communications in Statistics - Theory and Methods, 2000, 29, 1089-1113.	1.0	1
76	A Permutation Two One-Sided Tests Procedure to Detect Minimal Fold Changes of Gene Expression Levels. Journal of Biopharmaceutical Statistics, 2008, 18, 808-826.	0.8	1
77	Commentary on â€œAccounting for the Interim Safety Monitoring of an Adverse Event Upon Termination of a Clinical Trialâ€• Journal of Biopharmaceutical Statistics, 2008, 18, 641-643.	0.8	1
78	Sample size determination for within-device precision. Journal of Chemometrics, 2014, 28, 202-211.	1.3	1
79	Statistical Evaluation of Quality Performance on Genomic Composite Biomarker Classifiers. Journal of the Formosan Medical Association, 2008, 107, S28-S34.	1.7	0
80	Guest Editors' Note. Journal of Biopharmaceutical Statistics, 2009, 20, 1-2.	0.8	0
81	Evaluation of Linearity in Assay Validation. , 2010, , 467-474.		0
82	Authors' reply to the letter to the editor by L. Chen and Y. X. Liu. Pharmaceutical Statistics, 2012, 11, 343-345.	1.3	0
83	Addressing Loss of Efficiency Due to Misclassification Error in Enriched Clinical Trials for the Evaluation of Targeted Therapies Based on the Cox Proportional Hazards Model. PLoS ONE, 2016, 11, e0153525.	2.5	0
84	Targeted Clinical Trials. , 2010, , 1331-1337.		0
85	Therapeutic Equivalence. , 2010, , 1349-1353.		0
86	Equivalence Trials. , 2010, , 459-463.		0
87	Bridging Studies. , 2010, , 208-211.		0
88	Enrichment Design. , 2012, , 456-458.		0
89	Evaluation of Linearity in Assay Validation. , 2012, , 467-474.		0
90	Bridging Studies. , 2012, , 208-211.		0